Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 435,674
  • Shares Outstanding, K 12,739
  • Annual Sales, $ 171,550 K
  • Annual Income, $ -8,630 K
  • 60-Month Beta 0.61
  • Price/Sales 2.71
  • Price/Cash Flow N/A
  • Price/Book 1.87
Trade EGRX with:

Options Overview Details

View History
  • Implied Volatility 54.56% ( -4.07%)
  • Historical Volatility 58.77%
  • IV Percentile 75%
  • IV Rank 49.97%
  • IV High 75.02% on 12/13/21
  • IV Low 34.13% on 11/16/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 255
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 2,850
  • Open Int (30-Day) 1,590

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 1.15
  • Number of Estimates 1
  • High Estimate 1.15
  • Low Estimate 1.15
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +367.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.72 +6.15%
on 08/10/22
46.05 -22.28%
on 07/18/22
-8.41 (-19.03%)
since 07/12/22
3-Month
33.72 +6.15%
on 08/10/22
49.00 -26.96%
on 05/27/22
-8.41 (-19.03%)
since 05/12/22
52-Week
33.72 +6.15%
on 08/10/22
58.25 -38.56%
on 10/04/21
-11.95 (-25.03%)
since 08/12/21

Most Recent Stories

More News
Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript

EGRX earnings call for the period ending June 30, 2022.

EGRX : 35.79 (+4.65%)
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 35.79 (+4.65%)
LHDX : 3.18 (-0.31%)
Eagle Pharmaceuticals Reports Second Quarter 2022 Results

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total...

EGRX : 35.79 (+4.65%)
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for...

EGRX : 35.79 (+4.65%)
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the...

MRVI : 26.60 (-0.67%)
EGRX : 35.79 (+4.65%)
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25...

BMY : 75.57 (+1.49%)
LLY : 308.08 (+2.29%)
TEVA : 11.21 (+1.08%)
EGRX : 35.79 (+4.65%)
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the...

EGRX : 35.79 (+4.65%)
4 Pharmaceutical Stocks with Tremendous Growth Potential

The global pharmaceutical industry has witnessed robust growth over the past few years. The rapidly aging population and continued breakthroughs in drug development are expected to keep driving the industry’s...

ASRT : 3.80 (unch)
BAYRY : 13.9100 (+4.35%)
EGRX : 35.79 (+4.65%)
MRK : 91.02 (+2.35%)
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and...

EGRX : 35.79 (+4.65%)
Press the Buy Button on These 5 High Earnings Yield Picks Now

One could invest in high earnings yield stocks like Eagle Pharmaceuticals (EGRX), Cabot (CBT), Meritage Homes (MTH), Griffon (GFF) and APA Corp (APA) to fetch handsome long-term rewards.

APA : 34.70 (-0.40%)
MTH : 89.17 (+1.93%)
CBT : 76.27 (+2.44%)
EGRX : 35.79 (+4.65%)
GFF : 33.51 (-0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 39.05
2nd Resistance Point 37.77
1st Resistance Point 36.78
Last Price 35.79
1st Support Level 34.51
2nd Support Level 33.23
3rd Support Level 32.24

See More

52-Week High 58.25
Fibonacci 61.8% 48.88
Fibonacci 50% 45.98
Fibonacci 38.2% 43.09
Last Price 35.79
52-Week Low 33.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar